Incyte shares slip as PhII flop signals new problems ahead

Incyte ($INCY) took a nasty hit on its share price today after it reported that a combo study of Jakafi (ruxolitinib) and regorafinib (Bayer's Stivarga) failed a Phase II study on colorectal cancer. An interim analysis of the data concluded that the trial was a flop and analysts concluded that the risk of failure for pancreatic cancer, as well solid tumors in general, has gone up considerably. Incyte's shares dropped about 10% on the news. Not all analysts are so bearish, but in today's bear market for biotech stocks bad news is heavily amplified. Release

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.